This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 25/3/585    most recent 01.ATV.0000154140.73570.00v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duez, H. Articles by Staels, B. Search for Related Content PubMed PubMed Citation Articles by Duez, H. Articles by Staels, B. Related Collections Genetically altered mice Clinical Studies Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:585.)
© 2005 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator-Activated Receptor Modulation

Hélène Duez; Bruno Lefebvre; Philippe Poulain; Inés Pineda Torra; Frédéric Percevault; Gérald Luc; Jeffrey M. Peters; Frank J. Gonzalez; Romain Gineste; Stéphane Helleboid; Vladimir Dzavik; Jean-Charles Fruchart; Catherine Fiévet; Philippe Lefebvre; Bart Staels

From UR.545INSERM, Département d’Athérosclérose (H.D., P.P., I.P.T., F.P., G.L., J.-C.F., C.F., B.S.), Institut Pasteur Lille and Faculté de Pharmacie, Université de Lille2, France; UR.459INSERM, Biologie Moléculaire des Récepteurs Nucléaires (B.L., P.L.), Faculté de Médecine Lille, France; the Department of Veterinary Science (J.M.P.), Center for Molecular Toxicology, Pennsylvania State University, Hershey, Penn; the Laboratory of Metabolism (F.J.G.), National Cancer Institute, National Institute of Health, Bethesda, Md; GENFIT.SA (R.G., S.H.), Loos, France; and Cardiac Catherization Laboratory & Interventional Cardiology (V.D.), University Health Network, Toronto, Canada.

Correspondence to Hélène Duez or Prof Bart Staels, UR545INSERM, Département d’Athérosclérose, Institut Pasteur Lille, 1 rue Calmette, 59019 Lille, France. E-mail helene.duez{at}pasteur-lille.fr or bart.staels@pasteur-lille.fr

Objective— The objective of this trial was to study the effects of fenofibrate (FF) and gemfibrozil (GF), the most commonly used fibrates, on high-density lipoprotein (HDL) and apolipoprotein (apo) A-I.

Methods and Results— In a head-to-head double-blind clinical trial, both FF and GF decreased triglycerides and increased HDL cholesterol levels to a similar extent, whereas plasma apoA-I only increased after FF but not GF. Results in human (h) apoA-Itransgenic (hA-ITg) peroxisome proliferator-activated receptor (PPAR) –/– mice demonstrated that PPAR mediates the effects of FF and GF on HDL in vivo. Although plasma and hepatic mRNA levels of hapoA-I increased more pronouncedly after FF than GF in hA-ITgPPAR+/+ mice, both fibrates induced acylCoAoxidase mRNA similarly. FF and GF transactivated PPAR with similar activity and affinity on a DR-1 PPAR response element, but maximal activation on the hapoA-I DR-2 PPAR response element was significantly lower for GF than for FF. Moreover, GF induced recruitment of the coactivator DRIP205 on the DR-2 site less efficiently than did FF.

Conclusion— Both GF and FF exert their effects on HDL through PPAR. Whereas FF behaves as a full agonist, GF appears to act as a partial agonist due to a differential recruitment of coactivators to the promoter. These observations provide an explanation for the differences in the activity of these fibrates on apoA-I.

In hyperlipidemic patients and human apolipoprotein A-Itransgenic (hA-ITg) mice, fenofibrate (FF) and gemfibrozil (GF) increase HDL cholesterol, whereas apoA-I levels only increased after FF. Because of differential coactivator recruitment to the promoter, FF and GF, respectively, behave as full and partial PPAR agonists, likely explaining the clinical differences in the activity of these fibrates on apoA-I.

Key Words: apolipoprotein A-I • high-density lipoprotein • fibrates • peroxisome proliferator-activated receptor • selective PPAR modulator

This article has been cited by other articles:

				M. J. Chapman, W. Le Goff, M. Guerin, and A. Kontush Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors Eur. Heart J., October 12, 2009; (2009) ehp399v1. [Abstract] [Full Text] [PDF]

				U. Savas, D. E. W. Machemer, M.-H. Hsu, P. Gaynor, J. M. Lasker, R. H. Tukey, and E. F. Johnson Opposing Roles of Peroxisome Proliferator-activated Receptor {alpha} and Growth Hormone in the Regulation of CYP4A11 Expression in a Transgenic Mouse Model J. Biol. Chem., June 12, 2009; 284(24): 16541 - 16552. [Abstract] [Full Text] [PDF]

				J. S. Millar, D. Duffy, R. Gadi, L. T. Bloedon, R. L. Dunbar, M. L. Wolfe, R. Movva, A. Shah, I. V. Fuki, M. McCoy, et al. Potent and Selective PPAR-{alpha} Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 140 - 146. [Abstract] [Full Text] [PDF]

				F. Gizard, T. Nomiyama, Y. Zhao, H. M. Findeisen, E. B. Heywood, K. L. Jones, B. Staels, and D. Bruemmer The PPAR{alpha}/p16INK4a Pathway Inhibits Vascular Smooth Muscle Cell Proliferation by Repressing Cell Cycle-Dependent Telomerase Activation Circ. Res., November 7, 2008; 103(10): 1155 - 1163. [Abstract] [Full Text] [PDF]

				J.-C. Fruchart, F. M Sacks, M. P Hermans, G. Assmann, W V. Brown, R. Ceska, M J. Chapman, P. M Dodson, P. Fioretto, H. N Ginsberg, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients Diabetes and Vascular Disease Research, November 1, 2008; 5(4): 319 - 335. [Abstract] [PDF]

				C. C. van der Hoogt, W. de Haan, M. Westerterp, M. Hoekstra, G. M. Dallinga-Thie, J. A. Romijn, H. M. G. Princen, J. W. Jukema, L. M. Havekes, and P. C. N. Rensen Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression J. Lipid Res., August 1, 2007; 48(8): 1763 - 1771. [Abstract] [Full Text] [PDF]

				J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF]

				J. P. Vanden Heuvel, J. T. Thompson, S. R. Frame, and P. J. Gillies Differential Activation of Nuclear Receptors by Perfluorinated Fatty Acid Analogs and Natural Fatty Acids: A Comparison of Human, Mouse, and Rat Peroxisome Proliferator-Activated Receptor-{alpha}, -{beta}, and -{gamma}, Liver X Receptor-{beta}, and Retinoid X Receptor-{alpha} Toxicol. Sci., August 1, 2006; 92(2): 476 - 489. [Abstract] [Full Text] [PDF]

				B. Okopien, R. Krysiak, and Z. S. Herman Effects of Short-Term Fenofibrate Treatment on Circulating Markers of Inflammation and Hemostasis in Patients with Impaired Glucose Tolerance J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1770 - 1778. [Abstract] [Full Text] [PDF]

				J. Ji, G. F. Watts, A. G. Johnson, D. C. Chan, E. M. M. Ooi, K.-A. Rye, A. P. Serone, and P. H. R. Barrett High-Density Lipoprotein (HDL) Transport in the Metabolic Syndrome: Application of a New Model for HDL Particle Kinetics J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 973 - 979. [Abstract] [Full Text] [PDF]

				D. Lan and D. L. Silver Fenofibrate Induces a Novel Degradation Pathway for Scavenger Receptor B-I Independent of PDZK1 J. Biol. Chem., June 17, 2005; 280(24): 23390 - 23396. [Abstract] [Full Text] [PDF]